ABSTRACT Multiple sclerosis has become an ever-increasing challenge to neurologists. With the release of the latest medications on the market, Brazilian neurologists feel divided between following their patients’ evolution in accordance with the strict rules established by the Brazilian Ministry of Health regarding drug distribution, or following disease progression and worsening in accordance with the evidence in the literature. Therefore, a systematic review of the main published treatment guidelines was conducted and an escalating therapy proposed for guiding multiple sclerosis patient treatment in Brazil
OBJECTIVE: It is estimated that circa 50,000 individuals have relapsing-remitting multiple sclerosis...
Introduction. Multiple sclerosis (MS) is the most common primary demyelinating disease affecting the...
Treatments for multiple sclerosis therapy are rapidly evolving. It is believed that new drugs will b...
ABSTRACT The expanding therapeutic arsenal in multiple sclerosis (MS) has allowed for more effective...
Recent changes to the diagnostic criteria for multiple sclerosis (MS) and new medications have had a...
O tratamento de pacientes com esclerose múltipla (EM) com imunomoduladores e, mais recentemente, com...
Objective : The prevalence of multiple sclerosis (MS) in Latin America varies across different studi...
We performed a web-based survey among German-speaking neurologists to evaluate the acceptance of the...
Objective: The prevalence of multiple sclerosis (MS) in Latin America varies across different studie...
Em razão dos avanços no conhecimento da esclerose múltipla (EM), dos novos critérios diagnósticos e ...
With the advent of new disease-modifying drugs, the treatment of multiple sclerosis is becoming incr...
Objective: It is estimated that circa 50,000 individuals have relapsing-remitting multiple sclerosis...
O crescent arsenal terapêutico na esclerose múltipla (EM) tem permitido tratamentos mais efetivos e ...
BACKGROUND In May 2021, a new guideline on the diagnosis and treatment of multiple sclerosis and ...
Background: In May 2021, a new guideline on the diagnosis and treatment of multiple sclerosis and re...
OBJECTIVE: It is estimated that circa 50,000 individuals have relapsing-remitting multiple sclerosis...
Introduction. Multiple sclerosis (MS) is the most common primary demyelinating disease affecting the...
Treatments for multiple sclerosis therapy are rapidly evolving. It is believed that new drugs will b...
ABSTRACT The expanding therapeutic arsenal in multiple sclerosis (MS) has allowed for more effective...
Recent changes to the diagnostic criteria for multiple sclerosis (MS) and new medications have had a...
O tratamento de pacientes com esclerose múltipla (EM) com imunomoduladores e, mais recentemente, com...
Objective : The prevalence of multiple sclerosis (MS) in Latin America varies across different studi...
We performed a web-based survey among German-speaking neurologists to evaluate the acceptance of the...
Objective: The prevalence of multiple sclerosis (MS) in Latin America varies across different studie...
Em razão dos avanços no conhecimento da esclerose múltipla (EM), dos novos critérios diagnósticos e ...
With the advent of new disease-modifying drugs, the treatment of multiple sclerosis is becoming incr...
Objective: It is estimated that circa 50,000 individuals have relapsing-remitting multiple sclerosis...
O crescent arsenal terapêutico na esclerose múltipla (EM) tem permitido tratamentos mais efetivos e ...
BACKGROUND In May 2021, a new guideline on the diagnosis and treatment of multiple sclerosis and ...
Background: In May 2021, a new guideline on the diagnosis and treatment of multiple sclerosis and re...
OBJECTIVE: It is estimated that circa 50,000 individuals have relapsing-remitting multiple sclerosis...
Introduction. Multiple sclerosis (MS) is the most common primary demyelinating disease affecting the...
Treatments for multiple sclerosis therapy are rapidly evolving. It is believed that new drugs will b...